FBXL5 and colorectal carcinoma: Our data demonstrate a new molecular mechanism, by which an uncharacterised antibacterial AM404 drug altering the oncogenic activity of FBXL5 receptor subunit of E3-ligase, to alter differentiation, migration and drug-resistant of CRC cells.